Recombinant Human NT-ProBNP protein

NT-ProANP (N-terminal pro-atrial natriuretic peptide) is a biologically inactive fragment derived from the precursor protein proANP, which is primarily synthesized and secreted by cardiac atrial myocytes in response to ventricular stretch, volume overload, or pressure stress. ANP itself is a key hormone involved in regulating blood pressure, fluid balance, and cardiovascular homeostasis. During proANP processing, the mature active hormone ANP (C-terminal 28-amino-acid peptide) is cleaved and co-released with NT-ProANP (the N-terminal 1–98 amino acid segment), making NT-ProANP a stable biomarker for assessing cardiac function.

Recombinant NT-ProANP refers to the engineered protein produced via molecular cloning and expression systems (e.g., E. coli, mammalian cells) to mimic the native peptide’s structure. Its production enables standardized research and clinical applications, particularly in studying heart failure, hypertension, and renal dysfunction. Unlike ANP, NT-ProANP has a longer plasma half-life, making it a reliable diagnostic/prognostic indicator in cardiovascular diseases. Recombinant versions are critical for developing immunoassays, calibrating diagnostic kits, and investigating pathophysiological mechanisms.

Current research focuses on optimizing expression systems to ensure proper post-translational modifications and bioactivity. Challenges include maintaining structural stability, avoiding aggregation, and achieving cost-effective large-scale production. Beyond diagnostics, recombinant NT-ProANP is explored for therapeutic potential, such as modulating natriuretic peptide pathways or serving as a decoy receptor target. Its role in early disease detection and personalized medicine continues to drive biotechnological advancements in this field.

NT-ProBNP (N-terminal pro-B-type natriuretic peptide) is a biologically inactive peptide fragment derived from the cleavage of prohormone proBNP, which is primarily secreted by cardiac ventricular myocytes in response to myocardial stretch and increased ventricular wall tension. As a key biomarker in cardiovascular diagnostics, NT-ProBNP plays a critical role in assessing heart failure, ventricular dysfunction, and other cardiac conditions. Unlike its counterpart BNP (B-type natriuretic peptide), NT-ProBNP has a longer plasma half-life (60-120 minutes) and greater stability, making it more reliable for clinical immunoassays.

Recombinant NT-ProBNP proteins are engineered using genetic recombination techniques to produce standardized, high-purity antigens for diagnostic and research applications. These proteins are typically expressed in heterologous systems such as *E. coli* or mammalian cell lines, followed by purification via affinity chromatography. The recombinant form retains the epitopes required for antibody recognition in diagnostic kits, ensuring consistency in assays like ELISA or chemiluminescent immunoassays (CLIA).

Clinically, recombinant NT-ProBNP serves as a calibration standard in commercial diagnostic platforms to quantify endogenous NT-ProBNP levels in patient blood. Elevated concentrations correlate with disease severity, aiding in heart failure diagnosis, prognosis, and therapeutic monitoring. In research, it facilitates studies on cardiac biomarker biology, assay development, and the exploration of pathophysiological mechanisms underlying cardiovascular diseases. Its recombinant production addresses batch variability issues inherent in native protein extraction, enhancing reproducibility in both diagnostic and experimental settings.